Related Experiment Video

Updated: Sep 12, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

NUAK kinases: Signaling mechanisms and therapeutic applications

Nicole M Cullen1, Peter Rosston2, Bakhtawar Tufail1

  • 1Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.

The Journal of Biological Chemistry
|August 7, 2025
PubMed

Insights

Novel kinases NUAK1 and NUAK2 are crucial in diseases but lack targeted drugs. This review explores their roles and the therapeutic potential of developing specific inhibitors for NUAK1 and NUAK2 signaling pathways.

Area of Science:

  • Biochemistry and Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Novel (NUAK) kinases 1 and 2 are AMP-activated protein-related kinases implicated in cancer and other diseases.
  • Most human kinases, including NUAK1 and NUAK2, remain underexplored with limited targeted therapies.
  • There is a significant need for selective inhibitors of NUAK1 and NUAK2 signaling.

Purpose of the Study:

  • To review the structure, regulation, and biological roles of NUAK1 and NUAK2.
  • To explore the expression profiles of NUAK1 and NUAK2 in cancerous versus non-cancerous tissues.
  • To assess the therapeutic potential of targeting NUAK kinase signaling pathways.

Main Methods:

  • Literature review of protein structure, upstream regulators, and downstream targets.
  • Analysis of NUAK1 and NUAK2 expression in various malignancies and non-cancerous conditions.
  • Summary of existing small molecule inhibitors for NUAK kinases in preclinical and clinical studies.

Main Results:

  • NUAK1 and NUAK2 play roles in cancer progression and other diseases.
  • Expression profiles differ between cancerous and non-cancerous tissues.
  • Several small molecule inhibitors targeting NUAK kinases have shown promise in preclinical models, with one in clinical trials.

Conclusions:

  • Targeting NUAK kinase signaling pathways offers therapeutic potential for various diseases, particularly cancer.
  • Selective small molecule inhibitors are key to exploiting this therapeutic value.
  • Further research into NUAK1 and NUAK2 is warranted to develop effective treatments.
Keywords:
AMP-activated protein–related kinase (ARK)novel (nua) kinases 1 and 2 (NUAK1 and NUAK2)phosphorylationserine/threonine protein kinasesmall-molecule kinase inhibitor

More Related Videos

Identification of Kinase-substrate Pairs Using High Throughput Screening11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.3K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K